Ger Brophy, GE Healthcare Medical Diagnostics

Ger Brophy, Ph.D., is General Manager, New Product Development at GE Healthcare Medical Diagnostics. In this role, Ger is responsible for the overarching R&D strategy encompassing in vivo and in vitro diagnostic technologies, with oversight of discovery (research) and clinical development; regulatory and medical affairs; project and portfolio management; product acquisition and licensing; R&D efficiency projects and collaborations across GE.

Previously, Ger led Strategic Planning & Licensing within the Medical Diagnostics business. He was centrally involved in the expansion of the business into the Personalized Medicine space through inorganic and organic investments in in vitro diagnostics and pathology.

Ger joined GE Healthcare through the acquisition of Amersham in 2004. Before joining the Medical Diagnostics business, Ger ran the Life Sciences Advanced Systems business in Sweden. The focus on that business was in the commercialization of improved tools for drug discovery. In that capacity he lead an R&D group of 200 researchers developing new products and services used in academia and Pharma to better understand disease.

Ger began his career in R&D developing high-throughput drug screening tools. He advanced to become Development Director for Amersham’s Bioassay’s business unit, leading a group of 60 people. Within GE Healthcare, he has held positions in Licensing, Business Development, and R&D.

Ger has had international assignments in the United Kingdom, Sweden and in Chicago and New Jersey. He relocated to New Jersey in August 2009.

Ger holds a Ph.D. in Molecular Biology.

Read Ger Brophy’s latest contributions to The Age of Personalized Medicine Blog